Thursday, May 29, 2003

Genentech Names Corsee Sanders Vice President, Biometrics and Business Operations, Medical Affairs

South San Francisco, Calif. -- May 29, 2003 --

Genentech, Inc. (NYSE: DNA) today announced the promotion of Corsee Sanders to vice president, Biometrics and Business Operations, Medical Affairs. Sanders will continue to report to Hal Barron, vice president, Medical Affairs.

In her position, Sanders is responsible for managing, analyzing and assisting in the interpretation of all clinical trial data collected within Medical Affairs. She is also responsible for managing the business operations of the department, its ongoing employee training efforts, the medical editing group and information technology within Medical Affairs.

"Drawing upon her strong statistical and technical expertise, Corsee has made significant contributions to advancing Genentech's clinical drug development during her nearly nine years at Genentech," said Barron. "I'm confident that Corsee's extensive experience, excellent management skills and strong leadership will enable her to play a very significant role in ensuring Genentech's robust pipeline translates into important therapies for patients with significant unmet needs."

Sanders, 46, joined Genentech in 1994 as associate director, Biostatistics, and was named director in 1998. Since that time, she has held positions as director of Biostatistics and Statistical Programming and senior director of Biometrics and Business Operations. Prior to joining Genentech, Sanders was the biostatistics associate director for allergy, asthma and cytokines at the Schering-Plough Research Institute in Kenilworth, New Jersey.

Sanders holds a Bachelor of Science in statistics and a Master of Science in statistics from the University of the Philippines. She also received a master's degree and a doctorate in statistics from the University of Pennsylvania Wharton School.

Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. Fifteen of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes ten biotechnology products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA. For press releases and additional information about the company, please visit http://www.gene.com.